These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 33241960)

  • 21. Pharmacokinetics, safety, tolerability and immunogenicity of FKB327, a new biosimilar medicine of adalimumab/Humira, in healthy subjects.
    Puri A; Niewiarowski A; Arai Y; Nomura H; Baird M; Dalrymple I; Warrington S; Boyce M
    Br J Clin Pharmacol; 2017 Jul; 83(7):1405-1415. PubMed ID: 28133772
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase I, randomized, double-blind, single-dose study to assess the pharmacokinetics, safety, and immunogenicity of the proposed biosimilar SCT630 and adalimumab in healthy Chinese subjects.
    Liu L; Qi L; Lei C; Wang Y; Zhang W; Liu Y; Li P; Bai H; Li Y; Li Y; Liu J; Xie L; Wang X
    Int Immunopharmacol; 2022 May; 106():108599. PubMed ID: 35193054
    [TBL] [Abstract][Full Text] [Related]  

  • 23. HLX11, a Proposed Pertuzumab Biosimilar: Pharmacokinetics, Immunogenicity, and Safety Profiles Compared to Three Reference Biologic Products (US-, EU-, and CN-Approved Pertuzumab) Administered to Healthy Male Subjects.
    Yang J; Lin L; Long Q; Zhang Q; Sun G; Zhou L; Wang Q; Zhu J; Li F; Hu W
    BioDrugs; 2022 May; 36(3):393-409. PubMed ID: 35594017
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of two biosimilarity studies of FKB327 with the adalimumab reference product: randomized phase 1 studies of single-blind, single-dose subcutaneous injection in healthy Japanese male participants.
    Yonemura T; Yazawa R; Haranaka M; Kawakami K; Takanuma M; Kanzo T; Stefanidis D; Arai Y
    BMC Pharmacol Toxicol; 2022 Jan; 23(1):6. PubMed ID: 34998419
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacokinetics, pharmacodynamics, safety, and immunogenicity of Pelmeg
    Roth K; Lehnick D; Wessels H; Höfler J; Gastl B; Jankowsky R
    Pharmacol Res Perspect; 2019 Oct; 7(5):e00503. PubMed ID: 31417680
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A randomized, double-blind, parallel-group, single‑dose, pharmacokinetic bioequivalence study of INTP24 and bevacizumab in healthy adult men.
    Singh I; Patel R; Patel A; Jose V
    Cancer Chemother Pharmacol; 2020 Aug; 86(2):193-202. PubMed ID: 32627073
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A phase 1, randomized, open-label, single-dose study to assess the relative bioavailability of a subcutaneous dose of FKB327 when administered using a prefilled syringe, a prefilled auto-injector, or a vial with disposable syringe in healthy subjects.
    Bush J; Kawakami K; Muniz R
    BMC Pharmacol Toxicol; 2019 Dec; 20(1):87. PubMed ID: 31888742
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A randomized phase I clinical trial comparing the pharmacokinetic, safety, and immunogenicity of potential biosimilar recombinant human HER2 monoclonal antibody for injection and trastuzumab in healthy Chinese adults.
    Wang J; Niu S; Dong W; Wei L; Ou L; Zhang T; Zhang L; Nie X; Wang Q; Shen T; Wang Q; Xia L; Liu G; Jin J; Zheng Q; Song H; Fang Y
    Expert Opin Investig Drugs; 2020 Jul; 29(7):755-762. PubMed ID: 32594779
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Global Phase I Clinical Study Comparing the Safety and Pharmacokinetics of Proposed Biosimilar BAT1706 and Bevacizumab (Avastin
    Wu X; Wynne C; Xu C; Gan Y; Wang C; Thomas BE; Yu JC; Li S; Zhang L
    BioDrugs; 2019 Jun; 33(3):335-342. PubMed ID: 31016568
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A Randomized, Double-Blind, Parallel-Controlled Phase I Study Comparing the Pharmacokinetics, Safety, and Immunogenicity of SCT510 to Bevacizumab (Avastin
    Wu J; Wu G; Xie L; Lv D; Xu C; Zhou H; Wu L; Zhang J; Shentu J
    Drugs R D; 2023 Jun; 23(2):175-183. PubMed ID: 37247166
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacokinetic Similarity and Comparative Pharmacodynamics, Safety, Efficacy, and Immunogenicity of DRL_RI Versus Reference Rituximab in Biologics-Naïve Patients with Moderate-to-Severe Rheumatoid Arthritis: A Double-Blind, Randomized, Three-Arm Study.
    Haridas VM; Katta R; Nalawade A; Kharkar S; Zhdan V; Garmish O; Lopez-Lazaro L; Batra SS; Kankanwadi S
    BioDrugs; 2020 Apr; 34(2):183-196. PubMed ID: 32052313
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A randomized, single-blind, single-dose, parallel-group study in healthy subjects to demonstrate the pharmacokinetic equivalence of trastuzumab and its biosimilar.
    Wang Y; Liu Z; Deng Q; Su Z; Xue J; Zhao Y; Yang H
    Expert Opin Drug Metab Toxicol; 2023; 19(11):849-855. PubMed ID: 37526387
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacokinetic equivalence, comparable safety, and immunogenicity of an adalimumab biosimilar product (M923) to Humira in healthy subjects.
    Hillson J; Mant T; Rosano M; Huntenburg C; Alai-Safar M; Darne S; Palmer D; Pavlova BG; Doralt J; Reeve R; Goel N; Weilert D; Rhyne PW; Chance K; Caminis J; Roach J; Ganguly T
    Pharmacol Res Perspect; 2018 Feb; 6(1):. PubMed ID: 29417761
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Biosimilarity of HS-20090 to Denosumab in healthy Chinese subjects: a randomized, double-blinded, pharmacokinetics/pharmacodynamics study.
    Lin Y; Yang H; Yang X; Guo C; Yang S; Yang G; Wu Q; Pan C; Sun C; Li C; He L; Huang J; Pei Q
    Expert Opin Investig Drugs; 2022 Oct; 31(10):1125-1132. PubMed ID: 36112084
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An Open-Label, Randomized, Single-Dose, Crossover, Comparative Pharmacokinetics Study of YLB113 and the Etanercept Reference Product in Healthy Adult Male Subjects.
    Shennak M; Al-Jaouni R; Kshirasagar S; Kasibhatta RS; Godse N; Al-Ghazawi A; Vittala P; Bakhle D
    Eur J Drug Metab Pharmacokinet; 2020 Aug; 45(4):467-475. PubMed ID: 32172488
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Single-Dose Pharmacokinetics, Pharmacodynamics and Immunogenicity, and Multiple-Dose Immunogenicity of INTP5 (Pegfilgrastim Biosimilar) Versus Reference Pegfilgrastim in Healthy Subjects.
    Singh I; Attrey A; Garg A; Patel R; Jose V
    Clin Drug Investig; 2021 Jan; 41(1):29-42. PubMed ID: 33236287
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A phase I, randomized, double-blind, single-dose pharmacokinetic study to evaluate the biosimilarity of SB16 (proposed denosumab biosimilar) with reference denosumab in healthy male subjects.
    Lee HA; Kim S; Seo H; Kim S
    Expert Opin Investig Drugs; 2023; 32(10):959-966. PubMed ID: 37870163
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Proposed biosimilar pegfilgrastim shows similarity in pharmacokinetics and pharmacodynamics to reference pegfilgrastim in healthy subjects.
    Nakov R; Gattu S; Wang J; Velinova M; Schaffar G; Skerjanec A
    Br J Clin Pharmacol; 2018 Dec; 84(12):2790-2801. PubMed ID: 30079636
    [TBL] [Abstract][Full Text] [Related]  

  • 39. PF-06881894, a Proposed Biosimilar to Pegfilgrastim, Versus US-Licensed and EU-Approved Pegfilgrastim Reference Products (Neulasta
    Moosavi S; Borema T; Ewesuedo R; Harris S; Levy J; May TB; Summers M; Thomas JS; Zhang J; Yao HM
    Adv Ther; 2020 Jul; 37(7):3370-3391. PubMed ID: 32524499
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A randomised trial comparing the pharmacokinetics and safety of the biosimilar CT-P6 with reference trastuzumab.
    Esteva FJ; Stebbing J; Wood-Horrall RN; Winkle PJ; Lee SY; Lee SJ
    Cancer Chemother Pharmacol; 2018 Mar; 81(3):505-514. PubMed ID: 29330636
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.